Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 30;10(11):e005619. doi: 10.1136/jitc-2022-005619

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Immunohistochemical analysis of tumors among different treatment groups. (A with B, C) CD8 staining for CD8+T cells and ANK61 staining for natural killer (NK) cells in the treated tumors demonstrate a significantly higher number of CD8+ T cells and NK cells (brown color) in the triple combination treatment (RFH+LTX-315 (L-315)+DOX) group, compared with other seven treatment groups (***p<0.001). (A with D) The Foxp3 staining for regulatory T cells (Tregs, brown color) further confirms significantly decreased numbers of Tregs in the triple combination treatment, compared with other seven treatment groups (***p<0.001) (Scale bars, 20 µm). n=6 in each group. Error bars represent SD. RFH, radiofrequency hyperthermia.